Study to Evaluate JCXH-211 as Monotherapy in Patients With Malignant Solid Tumors

Inclusion Criteria:

• Male or female patients 18-75

• Patients with malignant solid tumors that have been diagnosed by pathology and/orcytology

• Patients who have progressed on or who cannot tolerate available therapies or forwhom curative therapy does not exist

• Patients with at least one non-injected measurable tumor lesion per RECIST v1.1

• Patients with lesions suitable for intratumoral injection (the lesion length is atleast 10mm and not exceeding 80mm)

• Patients enrolled in the Skin/subcutaneous lesions and deep （visceral） lesionsstages of Phase Ia must agree to provide pre- and post-treatment tumor biopsytissues

• Patients must have adequate organ and marrow functions

• Patients with treated brain metastases are eligible if meeting protocol'srequirement

• Patients must be ≥ 4 weeks beyond treatment with any chemotherapy (6 weeks fornitrosoureas or mitomycin C), hormonal, biological, targeted agents, otherinvestigational therapy or radiotherapy

Exclusion Criteria:

• Patients who have received prior IL-12 either alone or as part of a treatmentregimen

• Patients who have received prior therapy with an immuno-oncology agent and werediscontinued from that treatment due to a Grade 3 or higher immune-related adverseevent (irAE)

• Patients requiring therapeutic doses of anticoagulation

• Patients with tumors that impinge on major airways, blood vessels, or nerve bundles

• Patients with a history of autoimmune disease that has the possibility of recurrenceor active autoimmune disease that requires immunosuppressive medications

• Patients who had a major surgical procedure within 4 weeks prior to the first doseof study treatment

• Current or prior use of immunosuppressive medication within 2 weeks prior to thefirst dose of study treatment

• Patient with history of solid organ or allogenic bone marrow transplantation